NOVO B enters June nursing a 2.5% drop on Tuesday alone — extending a 3.4% weekly slide to DKK 277.65. The central tension is clear: a company with a near-best-in-class EPS surprise rank and a PE multiple that has compressed sharply now sits in a market debating whether the GLP-1 story is still intact or merely stabilising at lower prices.
Valuation is the loudest signal this week. The PE has dropped to 13.0x and EV/EBITDA has slid to 9.4x — both down over the past month, the EV/EBITDA in particular falling half a turn in 30 days. At these levels, Novo trades at a steep discount to the multiples it commanded a year ago. The earnings yield has risen to 7.7%, the highest it has been in some time, which tells you investors have stopped paying a premium for GLP-1 growth and started demanding a discount for execution risk. The factor scores reinforce the cheapness argument: the EV/EBIT rank is in the 82nd percentile of the universe, and the dividend score sits in the 98th. The price has simply come down faster than the business has deteriorated.
On the positioning side, the borrow market tells a quiet story that sits in contrast to the price action. Short interest in the Copenhagen-listed shares remains just 0.27% of the free float — barely moved week-on-week after touching 0.31% in late May, and well within its recent range. Availability is extraordinarily loose at roughly 67x current short interest, meaning the lending pool is nowhere close to stressed. Cost to borrow has actually eased back to 1.26% from a brief spike to 1.80% earlier in May. The selling pressure this week did not come from a surge in new shorting — it came from long holders reducing exposure, which is a different animal entirely. For US-listed NVO ADRs, the picture is sharper: short interest there jumped 53% in a single week to 21.8 million shares, according to ORTEX data published Tuesday. That divergence — aggressive shorting in the US instrument, almost no activity in the home-market stock — is worth watching.
Goldman Sachs reiterated its Neutral rating on the stock today, June 3, and flagged the Wegovy pill launch in the UAE as a sign of global ambition without changing the core view. That is consistent with broader analyst caution: the Street is not bearish enough to sell aggressively but not constructive enough to buy the dip. Analyst price target data in the ORTEX database is stale and cannot be reliably quoted here, but the tone from Goldman — the last named action — is one of disciplined fence-sitting. The bull case centres on oral semaglutide expanding the addressable market into populations that resist injections; the bear case is that oral bioavailability limits and emerging competition from oral GLP-1 rivals will erode pricing power before volume can compensate.
Ownership concentration remains a structural feature of the stock. Novo Holdings — the controlling foundation — holds 28.3% of shares and has not moved its position. BlackRock, Vanguard, and Capital Research have each added modestly over the past quarter, with Capital Research building a fresh stake of 17.3 million shares as recently as April 30. Geode added 5.3 million shares in the same reporting period. These are passive and quasi-passive flows, not conviction trades, but they set a floor on the register that limits the kind of forced-selling dynamics that can amplify drawdowns in more loosely held names.
Next earnings are scheduled for August 5. The most recent print, on May 6, delivered a 3.4% one-day gain and held a 4.7% five-day move. The prior event in March delivered a 3.1% loss. The setup into August — compressed valuation, loose borrow conditions, muted short interest in the home market — will be shaped by what trial data updates and geographic rollout news emerge in the weeks ahead, including any further geographic expansion of the Wegovy pill beyond the UAE.
See the live data behind this article on ORTEX.
Open NOVO B on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
